lamivudine has been researched along with HIV in 160 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 35 (21.88) | 18.2507 |
| 2000's | 62 (38.75) | 29.6817 |
| 2010's | 52 (32.50) | 24.3611 |
| 2020's | 11 (6.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YC; Chu, CK; Du, J; Lin, JS; Newton, MG; Schinazi, RF; Surzhykov, S | 1 |
| Chen, SH; Cheng, YC; Doyle, TW; Dutschman, GE; Gullen, EA; King, I; Mao, J; Wang, Q | 1 |
| Gochfeld, DJ; Hamann, MT | 1 |
| Austin, DJ; Cheng, YC; Chung, R; Dutschman, GE; Fu, L; Gullen, EA; Huang, ES; Lee, Y; Li, Y; Yeo, H; Zhu, JL | 1 |
| Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY | 1 |
| Motiee, F; Sohrabi, MR; Valaee, M | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
| Davis, CC; Hassounah, S; Heredia, A; Kashanchi, F; Le, NM; Medina-Moreno, S; Mesplede, T; Oliveira, M; Zapata, JC | 1 |
| Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
| Belmonti, S; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Cao, TZ; He, Y; Liu, JY; Liu, XN; Rao, M; Song, Y; Sun, LQ; Tian, YM; Wang, H; Xu, LM; Zhang, LK; Zhao, F; Zhou, Y | 1 |
| Basu, A; Biswas, A; Das, BK; Nischal, N; Soneja, M; Sood, R; Wig, N | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Bernheimer, J; Fairlie, L; Fick, C; Kuhn, L; Sipambo, N | 1 |
| Cochrane, S; Daniel, J; Forsyth, S; Smit, E | 1 |
| Alfredo, C; Auld, A; Bhatt, N; Bila, D; Buck, WC; Cossa, L; DeVos, J; Houston, J; Jani, I; Jobarteh, K; Macassa, E; Sabatier, J; Sousa, A; Vaz, P; Yang, C | 1 |
| Chen, QY; Fang, ZL; Harrison, TJ; Hu, LP; Jia, HH; Li, KW; Liang, SJ; Ren, CC; Wang, C; Wang, XY; Yang, QL | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Kan, W; Leng, X; Liao, L; Liu, P; Ruan, Y; Shao, Y; Wang, J; Xing, H; Xu, W; Yan, J; You, Y; Zuo, Z | 1 |
| Rijnders, BJA; Rokx, C | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Archary, M; Bobat, R; Hennig, S; LaRussa, P; Mcllleron, H; Sibaya, T; Wiesner, L | 1 |
| Briñón, MC; Esteve-Romero, J; Gualdesi, MS; Raviolo, MA | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Abbas, SQ; Abro, AG; Baig-Ansari, N; Kazi, MA; Mir, F; Qamar, FN; Rizvi, A; Zaidi, AK | 1 |
| Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Chang, JB; Chen, H; Cui, XQ; Dai, SX; Huang, JF; Liu, YJ; Luo, RH; Peng, YM; Wang, RR; Yang, QH; Zhang, XJ; Zheng, YT | 1 |
| Bartlett, JA; Crump, JA; Grossmann, H; Masenga, EJ; Mavura, DR; Minja, E | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| He, C; Hsi, JH; Kan, W; Leng, X; Liao, L; Ruan, Y; Shao, Y; Wang, J; Xing, H | 1 |
| Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Gededzha, MP; Lukhwareni, A; Mphahlele, MJ; Rakgole, JN; Selabe, SG | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Bessong, PO; Gachara, G; Kimbi, HK; Lum, E; Magoro, T; Mavhandu, L; Ndip, RN | 1 |
| Brandão-Mello, CE; Brett-Smith, H; Cassetti, I; Gazzard, B; Hall, A; Huang, AK; Mendes-Corrêa, MC; Pessôa, MG; Phiri, P; Soriano, V | 1 |
| Adams, E; Baert, L; Hoogmartens, J; Pendela, M; Rosier, J; Van den Mooter, G; Van Gyseghem, E | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Barr, EA; Davies, JK; Forster-Harwood, J; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, SM; Salbenblatt, CR; Soda, E; Vazquez, A; Weinberg, A | 1 |
| Evans, J; Jarrin, I; Lafuente-Lafuente, C; Mazeron, MC; Parrinello, M; Schnepf, N; Sellier, P; Simoneau, G | 1 |
| Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R | 1 |
| Berg, CL; Coffin, CS; Curry, MP; Dove, LM; Nissen, NN; Ragni, M; Regenstein, FG; Roland, ME; Sherman, KE; Stock, PG; Terrault, NA | 1 |
| Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA | 1 |
| Nwankwo, N; Seker, H | 1 |
| Ekwunife, OI; Iwuamadi, UI; Udeogaranya, OP; Ukwe, CV | 1 |
| Chen, XY; Gui, X; Yang, RR; Zhu, Y | 1 |
| Deng, L; Gao, S; Gui, X; Liang, K; Rong, Y; Xiong, Y; Yan, Y; Yang, R; Zhang, Y | 1 |
| Rizzardini, G; Zucchi, P | 1 |
| Dou, Z; Durako, S; Jiao, JH; Ma, Y; Xu, J; Yu, L; Zhang, F; Zhao, Y | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Alvarez, Y; Hioe, CE; Nàdas, A; Tuen, M | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Aguilar, C; Brown, RS; Buti, M; Fagan, EA; Leu, CS; Pereira, MR; Tilson, HH; Verna, EC | 1 |
| Abel, F; Behrens, G; Domingo, P; Maserati, R; Pearce, G; Rieger, A; Wang, H | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Banerjee, A; Biswas, A; Chakrabarti, S; Chakravarty, R; Datta, S; Guha, SK; Pal, A; Panigrahi, R; Saha, B; Sarkar, N | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Antinori, A; Bedini, A; Bertoli, A; Borghi, V; Bugarini, R; Cossarizza, A; D'Arrigo, R; Esposito, R; Mongiardo, N; Mussini, C; Perno, CF | 1 |
| Adachi, M; Antonelli, G; Bambacioni, F; Focher, F; Riva, E; Sampath, J; Scagnolari, C; Schuetz, JD; Turriziani, O | 1 |
| Livrozet, JM; Miossec, P; Touraine, JL; Wegrzyn, J | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Harel, M; Izopet, J; Joly, V; Lastère, S; Meiffrédy, V; Peytavin, G; Tamalet, C; Yéni, P; Zeng, AF | 1 |
| Khanna, N | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Pendergrass, S; Qazi, S; Uckun, FM; Venkatachalam, TK | 1 |
| Benhamou, Y | 1 |
| Ait-Khaled, M; Craig, C; Griffin, P; Stone, C; Tisdale, M | 1 |
| Cohen, J | 2 |
| Burchett, SK; Ciupak, G; Delke, I; Frenkel, L; Hitti, J; Huang, S; Mathias, A; Mofenson, L; Rathore, M; Samelson, R; Shapiro, DE; Smith, ME; Unadkat, JD; Wade, NA; Watts, DH; Yasin, S | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Chan, KC; Lee, SS; Wong, KH | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Thio, CL | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Jenny-Avital, ER | 1 |
| Brown, J; Heffernan-Vacca, S; Millery, M; Neu, N; Stimell, M | 1 |
| Farthing, C; Khanlou, H | 1 |
| Andreotti, M; Ceffa, S; Cusato, M; Germano, P; Giuliano, M; Guidotti, G; Liotta, G; Loureiro, S; Mancini, MG; Marazzi, MC; Palombi, L; Pirillo, MF; Regazzi, M; Vella, S; Villani, P | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Chow, DC; Khawcharoenporn, T; Shikuma, CM; Williams, AE | 1 |
| Bendenoun, M; Mazeron, MC; Sanson-le Pors, MJ; Schnepf, N; Sellier, P; Zini, JM | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Acosta, EP; Bryson, Y; Capparelli, EV; Holland, D; Luzuriaga, K; Mirochnick, M; Patel, P; Tremoulet, AH; Wara, D; Zorrilla, C | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| Asif, G; Hurwitz, SJ; Schinazi, RF | 1 |
| Anglaret, X; Dabis, F; Dakoury-Dogbo, N; Diakite, N; Duvignac, J; Grundmann, C; Karcher, S; Kouadio, B; Marlink, R; Seyler, C; Toure, S; Traore, M | 1 |
| Boucher, CA; Cammack, N; Hill, A; Ingrand, D; Loveday, C; Robert, C; Weber, J | 1 |
| Bartlett, JA; Benoit, SL; Ehmann, WC; Fallon, MA; Johnson, VA; Quinn, JB; Rubin, M; Self, PL; Sepulveda, GE; Tsoukas, C | 1 |
| Rowe, PM | 1 |
| Bartlett, J; Eron, J; Gilbert, C; Hill, AM; Johnson, J; Johnson, VA; Keller, A; Kuritzkes, DR; Phillips, AN | 1 |
| Ahle, D; Bushnell, S; Chang, C; Collins, ML; Detmer, J; Fine, E; Ho, DD; Horn, T; Irvine, B; Kolberg, J; Shen, LP; Tyner, D; Urdea, MS; Zayati, C | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Crespo, J; Pons-Romero, F | 1 |
| Adams, O; Horneff, G; Wahn, V | 1 |
| Kaiser, R; Rockstroh, JK; Sauerbruch, T; Spengler, U; Theisen, A | 1 |
| Balis, FM; Brouwers, P; Deutsch, PJ; Jarosinski, PF; Ju, W; Mistry, G; Mueller, BU; Nelson, RP; Pizzo, PA; Sei, S; Sleasman, J; Smith, S; Steinberg, SM; Winchell, G; Wood, LV; Zeichner, S; Zwerski, S | 1 |
| Kibayashi, K; NG'walali, PM; Tsunenari, S | 1 |
| de Jong, JJ; de Wolf, F; Foudraine, NA; Jan Weverling, G; Jurriaans, S; Keet, IP; Lange, JM; Maas, J; Roos, MT; van Benthem, BH; Vandermeulen, K | 1 |
| Phillips, L | 1 |
| Asensi, V; Carton, JA; Maradona, JA; Martínez, A; Rodríguez, M | 1 |
| Aboulker, JP; Bazin, B; Brun-Vézinet, F; Calvez, V; Collin, G; Delaugerre, C; Descamps, D; Flandre, P; Meiffredy, V; Peytavin, G; Pialoux, G; Raffi, F; Robert-Delmas, S | 1 |
| Collier, AC; Havlir, DV; Hellmann, NS; Hirsch, MS; Petropoulos, CJ; Richman, DD; Sommadossi, JP; Tebas, P; Whitcomb, JM | 1 |
| Boschini, A; Calista, D | 1 |
| Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H | 1 |
| Chodakewitz, JA; Condra, JH; Emini, EA; Eron, JJ; Gonzalez, C; Gulick, RM; Havlir, D; Isaacs, R; Jonas, L; McMahon, D; Meibohm, A; Mellors, JW; Richman, DD; Valentine, FT | 1 |
| Atkinson, B; Isaacson, J; Knowles, M; Mazabel, E; Patick, AK | 1 |
| Arnedo, A; Gómez, CJ; Roca, B | 1 |
| Bechstein, WO; Berg, T; Hopf, U; Müller, AR; Neuhaus, P; Neuhaus, R; Rayes, N; Seehofer, D | 1 |
| Bucy, RP; Gnann, JW; Goepfert, PA; Kilby, JM; Miller, AP; Saag, MS; Sillers, M | 1 |
| Anderson, PL; Brundage, RC; Bushman, LR; Fletcher, CV; Kakuda, TN; Kawle, SP; Remmel, RP; Weller, D | 1 |
| Giménez-Doménech, R; Kindelán, JM; Madueño, J; Vidal-Verdú, E | 1 |
| Brotas, V; Cooper, D; Cutrell, A; Gathe, J; Hammer, SM; Hetherington, S; Hicks, C; Isaacs, R; Johnson, M; Keiser, P; Montaner, J; Raffi, F; Spreen, W; Staszewski, S; Steel, H; Thorborn, D; Tortell, S | 1 |
| Jankelevich, S; Mackall, CL; Mueller, BU; Nelson, RP; Nguyen, BY; Pizzo, PA; Serchuck, L; Sleasman, JW; Smith, S; Steinberg, SM; Wood, LV; Yarchoan, R; Zeichner, SL; Zwerski, S | 1 |
| Conant, M | 1 |
| Mascolini, M | 1 |
| Gilden, D | 1 |
| Chang, HE | 1 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Smart, T | 1 |
| Torres, G | 1 |
| Doepel, L; Folkers, G | 1 |
| Woodward, J | 1 |
| Delaney, WE; Locarnini, S; Shaw, T | 1 |
| Bassett, R; Collier, AC; Condra, J; Gilbert, P; Günthard, HF; Havlir, DV; Hirsch, MS; Ignacio, C; Levitan, D; Richman, DD; Tebas, P; Wong, JK | 1 |
| Bryant, ML; Cretton-Scott, E; Egron, D; el Kouni, MH; Faraj, A; Gosseli, G; Imbach, JL; Loi, AG; Martin, LT; Périgaud, C; Pierra, C; Placidi, L; Schinazi, RF; Sommadossi, JP | 1 |
| Boyle, BA | 1 |
| Boucher, CA; Cohen Stuart, JW; de Jong, D; Kaye, S; Kovacs, C; Righart, M; Schuurman, R; Visser, CJ; Wensing, AM | 1 |
| Korn, K; Schmidt, B; Schwingel, E; Walter, H; Werwein, M | 1 |
| Bartlett, JA; Bucy, RP; Fiscus, SA; Gryszowska, V; Miralles, GD; Ottinger, J; Pruitt, SK; Sevin, AD; Silberman, M | 1 |
| Beltrami, EM; Cardo, DM; de la Torre, N; Luo, CC | 1 |
| Cannon, D; Furman, PA; Lloyd, RM; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Sommadossi, JP; St Clair, M; Wilson, J | 1 |
| Boehme, RE; Cameron, JM; Figueiredo, HT; Gray, NM; Hart, GJ; Orr, DC; Penn, CR | 1 |
9 review(s) available for lamivudine and HIV
| Article | Year |
|---|---|
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Dideoxynucleosides; HIV; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2011 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
Topics: Acute Disease; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chronic Disease; Disease Progression; Drug Therapy, Combination; Fever; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Syndrome; Viral Load; Zidovudine | 2000 |
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Topics: 2-Aminopurine; Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; Antimetabolites; Antiviral Agents; Biological Availability; Cell Line; Clinical Trials as Topic; DNA Replication; DNA-Directed DNA Polymerase; DNA, Viral; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Famciclovir; Gene Products, pol; Hepatitis B; Hepatitis B virus; Hepatitis Viruses; Hepatitis, Animal; HIV; Humans; Lamivudine; Models, Animal; Molecular Sequence Data; Molecular Structure; Nucleosides; Organophosphonates; Sequence Alignment; Sequence Homology, Amino Acid; Species Specificity; Virus Replication | 2001 |
36 trial(s) available for lamivudine and HIV
| Article | Year |
|---|---|
Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
Topics: Anti-HIV Agents; Biological Availability; Body Weight; Child; Child Nutrition Disorders; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Biological; Nutritional Support; Severity of Illness Index; South Africa; Time Factors; Time-to-Treatment; Treatment Outcome; Viral Load | 2019 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Single-Blind Method; Virus Replication | 2008 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; Drug Administration Schedule; Drugs, Generic; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Malawi; Male; Nevirapine; Prospective Studies; Stavudine | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weight; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2011 |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV; HIV Infections; Humans; Lamivudine; Lipids; Lopinavir; Male; Medication Adherence; Middle Aged; Organophosphorus Compounds; Ritonavir; Treatment Outcome | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Genotype; HIV; HIV Infections; Humans; Lamivudine; Male; Mutation; RNA, Viral; Time Factors; Viral Load | 2002 |
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Mutation; Patient Compliance; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2002 |
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
Topics: Adult; Amniotic Fluid; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Metabolic Clearance Rate; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Viral Load | 2004 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; New York City; Patient Compliance; Prospective Studies; Regression Analysis; Sex Offenses; Zidovudine | 2007 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Lamivudine; Milk, Human; Nevirapine; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; RNA, Viral; Stavudine; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
Topics: Adult; AIDS-Related Complex; Antigen-Antibody Complex; Antiviral Agents; Dose-Response Relationship, Drug; HIV; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia; Zalcitabine | 1995 |
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biopterins; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Neopterin; Polymerase Chain Reaction; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pilot Projects; RNA, Viral; Viral Load; Zidovudine | 1998 |
A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
Topics: Adolescent; Adult; Biological Availability; Capsules; CD4 Lymphocyte Count; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infant; Lamivudine; Male; Suspensions; Viral Load; Virus Replication; Zidovudine | 1998 |
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Topics: Adult; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Homosexuality, Male; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Lamivudine for chronic hepatitis B and HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Topics: Anti-HIV Agents; Case-Control Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Patient Compliance; Treatment Failure; Viral Load; Zidovudine | 2000 |
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; HIV; HIV Infections; Humans; Indinavir; Kidney Calculi; Lamivudine; Male; Middle Aged; RNA, Viral; Viral Load; Viremia; Zidovudine | 2000 |
Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation.
Topics: 2-Aminopurine; Anti-HIV Agents; Antiviral Agents; Famciclovir; Hepatitis B; Hepatitis B virus; HIV; Humans; Lamivudine; Liver; Liver Transplantation; Prospective Studies; Reverse Transcriptase Inhibitors | 2000 |
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cytidine Triphosphate; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Middle Aged; Prospective Studies; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Thymine Nucleotides; Zidovudine | 2000 |
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Survival Analysis; Therapeutic Equivalency; Viral Load; Zidovudine | 2001 |
Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Leukocyte Common Antigens; Male; Protein Tyrosine Phosphatase, Non-Receptor Type 1; RNA, Viral; Viral Load; Zidovudine | 2001 |
Combination shows reduction in viral levels.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Lamivudine; Time Factors; Zidovudine | 1996 |
Drug combination shows benefits for AIDS patients with history of taking AZT.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Zidovudine | 1996 |
Phase II/III Trials of Viracept start.
Topics: Anti-HIV Agents; Blood; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Sulfonic Acids; Time Factors; Zidovudine | 1996 |
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lymphoid Tissue; Male; Middle Aged; Monocytes; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load | 2002 |
115 other study(ies) available for lamivudine and HIV
| Article | Year |
|---|---|
Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides.
Topics: Anti-HIV Agents; Antiviral Agents; Cytosine; Flucytosine; Hepatitis B virus; HIV; Humans; Indicators and Reagents; Molecular Conformation; Molecular Structure; Nucleosides; Structure-Activity Relationship | 1997 |
Synthesis and biological evaluation of a series of 2'-fluorinated-2',3'-dideoxy-2',3'-didehydro-(L)-nucleosides.
Topics: Antiviral Agents; Cell Line; Dideoxynucleosides; Fluorine; Hepatitis B virus; HIV; Humans | 1998 |
Isolation and biological evaluation of filiformin, plakortide F, and plakortone G from the Caribbean sponge Plakortis sp.
Topics: Animals; Antimalarials; Bromobenzenes; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dioxanes; Gas Chromatography-Mass Spectrometry; Hepatitis B; HIV; Humans; Jamaica; Lactones; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Mycobacterium tuberculosis; Neoplasms, Unknown Primary; Nuclear Magnetic Resonance, Biomolecular; Plasmodium berghei; Plasmodium falciparum; Porifera; Spectrometry, Mass, Electrospray Ionization; Tumor Cells, Cultured | 2001 |
Synthesis and antiviral activity of helioxanthin analogues.
Topics: Antiviral Agents; Benzofurans; Cytomegalovirus; Dioxoles; Hepacivirus; Hepatitis B virus; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 4, Human; HIV; Lactones; Lignans; Naphthalenes; Structure-Activity Relationship | 2005 |
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Rapid simultaneous analysis of anti human immunodeficiency virus drugs in pharmaceutical formulation by smart spectrophotometry based on multivariate calibration and least squares support vector machine methods.
Topics: Calibration; Drug Compounding; HIV; Lamivudine; Least-Squares Analysis; Spectrophotometry; Support Vector Machine; Zidovudine | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Lamivudine-resistant HIV
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Mice; Mutation; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
Topics: Adult; Anti-HIV Agents; DNA; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen.
Topics: Aged; Anti-HIV Agents; China; Dyslipidemias; HIV; HIV Infections; Humans; Lamivudine; Lipids; Risk Factors | 2020 |
Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; HIV; HIV Infections; Humans; India; Lamivudine; Male; Prevalence; Risk Factors; Viral Load; Zidovudine | 2021 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
Lamivudine monotherapy in children and adolescents: The devil is in the detail.
Topics: Adolescent; Anti-HIV Agents; Child; Disease Management; Drug Monitoring; Drug Resistance, Viral; Genes, Viral; HIV; HIV Infections; Humans; Lamivudine; Long-Term Care; Medication Adherence; Mutation; Viral Load | 2017 |
First reported case of integrase (R263K, G163R) and reverse transcriptase (M184V)-transmitted drug resistance from a drug-naive patient failing Triumeq.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation, Missense; Treatment Failure | 2018 |
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Mozambique; Nevirapine; Stavudine; Treatment Failure; Viral Load | 2020 |
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Topics: Adult; Anti-HIV Agents; China; Coinfection; DNA-Directed DNA Polymerase; Drug Resistance, Multiple, Viral; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Mutation; Prevalence; Tenofovir; Viral Load | 2018 |
Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Stavudine; Sustained Virologic Response; Tenofovir; Zidovudine | 2018 |
Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?
Topics: Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Development and validation of a stability indicating method for seven novel derivatives of lamivudine with anti-HIV and anti-HBV activity in simulated gastric and intestinal fluids.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Hepatitis B virus; HIV; Humans; Lamivudine; Limit of Detection; Reproducibility of Results; Reverse Transcriptase Inhibitors | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Pakistan; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.
Topics: Anti-HIV Agents; Azides; Cell Line; Deoxycytidine; Drug Resistance, Viral; Genotype; HIV; HIV Reverse Transcriptase; Humans; Lamivudine; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Protein Binding; Reverse Transcriptase Inhibitors; Virus Replication | 2014 |
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; RNA, Viral; Severity of Illness Index; Skin Diseases; Stavudine; Tanzania; Young Adult | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12.
Topics: Adult; Anti-Retroviral Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Treatment Failure | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactions; Female; HIV; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Nevirapine; Opportunistic Infections; Patient Dropouts; Retrospective Studies; Stavudine; Tuberculosis | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; DNA, Viral; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; South Africa; Viral Load | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocytes, Mononuclear; Pilot Projects; Polymerase Chain Reaction; Ritonavir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon.
Topics: Adolescent; Adult; Base Sequence; Cameroon; Child, Preschool; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Mutation; Phylogeny; Prevalence; Prospective Studies; Risk Factors; Sequence Analysis; Young Adult | 2017 |
Development of a liquid chromatographic assay for an anti-HIV tablet containing lamivudine, zidovudine and TMC278.HCL.
Topics: Anti-HIV Agents; Biological Assay; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; HIV; Humans; Lamivudine; Light; Molecular Structure; Nitriles; Pyrimidines; Reference Standards; Rilpivirine; Scattering, Radiation; Sensitivity and Specificity; Solvents; Spectrophotometry, Ultraviolet; Tablets; Zidovudine | 2009 |
Resistance to antiretrovirals in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Viral Load; Zidovudine | 2009 |
Truvada and Epivir are similar at suppressing HIV.
Topics: CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Lamivudine; Organophosphorus Compounds; Viral Load | 2009 |
Description of liver disease in a cohort of HIV/HBV coinfected patients.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-HIV Agents; Aspartate Aminotransferases; Cohort Studies; DNA, Viral; Female; Hepatitis B; HIV; HIV Infections; Humans; Lamivudine; Male; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Statistics, Nonparametric | 2010 |
Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Graft Survival; Hepatitis; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Immunoglobulins; Immunologic Deficiency Syndromes; Infections; Lamivudine; Liver Cirrhosis; Liver Failure; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Secondary Prevention; Treatment Outcome; Virus Diseases; Viruses | 2010 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Nevirapine; Stavudine; Zidovudine | 2010 |
A signal processing-based bioinformatics approach to assessing drug resistance: human immunodeficiency virus as a case study.
Topics: Amino Acid Sequence; Anti-HIV Agents; Computational Biology; Drug Resistance; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Infections; Humans; Lamivudine; Molecular Sequence Data; Mutation; Peptide Fragments; Phenylpropionates; Pyrimidines; Signal Processing, Computer-Assisted | 2010 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Feasibility Studies; Female; HIV; HIV Infections; Humans; Lamivudine; Linear Models; Male; Medication Adherence; Middle Aged; Nevirapine; Nigeria; Patient Satisfaction; Prospective Studies; Reminder Systems; Risk Factors; Self Report; Stavudine; Surveys and Questionnaires; Treatment Outcome | 2010 |
Interference of replication between hepatitis B and C viruses in patients infected with HIV.
Topics: Adult; Antibodies, Viral; CD4 Lymphocyte Count; Cell Line, Tumor; China; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Mutation; Plasmids; Risk Factors; RNA, Viral; Transfection; Virus Replication | 2011 |
Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Retrospective Studies; Risk Factors; RNA, Viral; Young Adult | 2011 |
Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asian People; CD4 Lymphocyte Count; China; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Sex Factors; Survival Rate; Treatment Outcome; Young Adult | 2011 |
In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Cytokines; Flow Cytometry; HIV; HIV Infections; Humans; In Vitro Techniques; Lamivudine; Th17 Cells; Virus Replication | 2012 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.
Topics: Adenine; Adult; Antiviral Agents; Congenital Abnormalities; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Phosphorous Acids; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Treatment Outcome | 2012 |
Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients.
Topics: Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV; HIV Infections; Humans; Immunosuppression Therapy; Lamivudine; Male; Sequence Analysis, DNA; Viral Load | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11.
Topics: Anti-HIV Agents; ATP-Binding Cassette Transporters; Biological Transport; Deoxycytidine Kinase; Drug Resistance, Multiple; HIV; Humans; Lamivudine; Multidrug Resistance-Associated Proteins; Nucleosides; T-Lymphocytes; Tumor Cells, Cultured; Zidovudine | 2002 |
Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; HIV; HIV Infections; Humans; Immunocompromised Host; Lamivudine; Male; Saquinavir; Stavudine; Treatment Outcome | 2002 |
[Exacerbation of chronic hepatitis B after discontinuing of antiretroviral therapy in HIV infection].
Topics: Adult; Anti-HIV Agents; Diagnosis, Differential; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Time Factors; Virus Replication | 2002 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.
Topics: Cells, Cultured; Dideoxynucleotides; Drug Resistance, Viral; Genotype; HIV; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Neutrophils; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Thymidine Monophosphate; Viral Plaque Assay; Zidovudine | 2004 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Topics: Adenine; Anti-HIV Agents; Cloning, Molecular; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Genotype; HIV; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
HIV/AIDS in China. A new treatment campaign, but with limited weapons.
Topics: Academies and Institutes; Acquired Immunodeficiency Syndrome; Anti-HIV Agents; China; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Foundations; HIV; HIV Infections; Humans; Lamivudine; Patents as Topic | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Screen for underlying HIV before antiviral treatment for HBV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Contraindications; Drug Resistance, Viral; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Treatment Failure | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
Topics: Adenine; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Antibodies; Humans; Lamivudine; Organophosphonates; Treatment Outcome | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
Lamivudine-associated macrocytosis in HIV-infected patients.
Topics: Adult; Anemia, Macrocytic; Erythrocyte Indices; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2007 |
Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Virus Activation | 2007 |
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.
Topics: Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Creatinine; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Meta-Analysis as Topic; Metabolic Clearance Rate | 2007 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cytidine Triphosphate; Dideoxynucleotides; HIV; HIV Infections; Humans; Inhibitory Concentration 50; Kinetics; Lamivudine; Models, Biological; Monte Carlo Method; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2007 |
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Administration Schedule; Female; Follow-Up Studies; HIV; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Nevirapine; Survival Analysis; Treatment Outcome; Zidovudine | 2008 |
AIDS mood upbeat--for a change.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; Gene Products, nef; Herpesviridae; HIV; Humans; Lamivudine; nef Gene Products, Human Immunodeficiency Virus; Sarcoma, Kaposi; Simian Immunodeficiency Virus; Virus Replication; Zalcitabine; Zidovudine | 1995 |
New guidelines set for occupational HIV exposure.
Topics: Accidents, Occupational; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Practice Guidelines as Topic; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[HIV: less resistance due to combined treatment].
Topics: Adult; Anti-HIV Agents; Computer Graphics; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Time Factors; Zidovudine | 1996 |
[HIV: to administer protease inhibitors early].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Time Factors; Zalcitabine; Zidovudine | 1996 |
Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1997 |
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.
Topics: Adenosine; Anti-HIV Agents; Cytidine; DNA; DNA, Viral; Drug Therapy, Combination; Guanosine; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Nelfinavir; Nucleic Acid Hybridization; RNA, Viral; Sulfonic Acids; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
[Lamivudine treatment: realities and expectations].
Topics: Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferons; Lamivudine; Polymerase Chain Reaction | 1997 |
Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Chemoprophylaxis after occupational exposure to human immunodeficiency virus in forensic autopsy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Forensic Medicine; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Occupational Exposure; Zidovudine | 1998 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Phenotype; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine | 2000 |
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 2000 |
Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Logistic Models; Male; Nelfinavir; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Stavudine; Substance Abuse, Intravenous | 2000 |
[Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in previously untreated patients from Andalusia. Andalusian Group for the Study of Infectious diseases (GAEI)].
Topics: Adult; Anti-HIV Agents; CD4 Antigens; Codon; Data Interpretation, Statistical; DNA, Viral; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Viral Load; Zidovudine | 2000 |
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1995 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Roaches of inner space.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Virulence; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
3TC treatment may slow HIV mutations, development of drug resistance.
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
Update on antivirals.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
New recommendations on health care worker exposure to HIV.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Drug Therapy, Combination; Guidelines as Topic; Health Personnel; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Risk Factors; Viral Load; Zidovudine | 1996 |
Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Retrospective Studies; RNA, Viral; Viral Load; Viremia; Virus Replication; Zidovudine | 2001 |
Antiviral activity and intracellular metabolism of bis(tButylSATE) phosphotriester of beta-L-2',3'dideoxyadenosine, a potent inhibitor of HIV and HBV replication.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Chromatography, High Pressure Liquid; Dideoxyadenosine; Dideoxynucleotides; DNA-Directed DNA Polymerase; Half-Life; Hematopoietic Stem Cells; Hepatitis B virus; Hepatocytes; HIV; Humans; Inhibitory Concentration 50; Lamivudine; Leukocytes, Mononuclear; Marmota; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tumor Cells, Cultured; Virus Replication | 2001 |
Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part 2.
Topics: Amantadine; Antiviral Agents; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Risk Factors | 2001 |
Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV; HIV Infections; Humans; Lamivudine; Mutation; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Load | 2001 |
Lamivudine (Epivir).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2000 |
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.
Topics: Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Gene Frequency; Genotype; HIV; Humans; Lamivudine; Microbial Sensitivity Tests; Zidovudine | 2002 |
Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen.
Topics: Adult; Anti-HIV Agents; Health Personnel; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Treatment Failure; Zidovudine | 2002 |
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Topics: Antiviral Agents; Emtricitabine; HIV; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stereoisomerism; Zalcitabine; Zidovudine | 1992 |
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.
Topics: Antiviral Agents; Base Sequence; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; DNA-Directed DNA Polymerase; HIV; Kinetics; Lamivudine; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Nucleotides; Peptide Chain Termination, Translational; Polyribonucleotides; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine | 1992 |